Delivers 2.6% Same-Store Sales Growth(1), 6% Revenue Growth Raises 2025 Outlook and Announces Chief Executive Officer Succession Plan MARKHAM, Ontario, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. ("Pet Valu" or the "Company") (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, today announced its financial results for the second quarter ended June 28, 2025.

Clermont-Ferrand (France), 21 July 2025 (17h45 CEST) –  CARBIOS (Euronext Growth Paris: ALCRB) announces the signing of a multi-year commercial agreement with Indorama Ventures, the global leader in PET production. This agreement covers the supply of biorecycled monomers from its Longlaville plant, which will be transformed into r-PET filaments by Indorama Ventures and then integrated by Michelin into the manufacturing of its tires.

Initiates Chapter 11 Proceeding via Pre-Packaged Plan of Reorganization Operations Across Business Segments to Continue Without Interruption During Chapter 11 Process and Beyond SAN FRANCISCO, July 21, 2025 (GLOBE NEWSWIRE) -- Wag! Group Co. (the “Company” or “Wag!

MARKHAM, Ontario, July 10, 2025 (GLOBE NEWSWIRE) -- Pet Valu Holdings Ltd. (“Pet Valu” or the “Company”) (TSX: PET), the leading Canadian specialty retailer of pet food and pet-related supplies, will release its financial results for the second quarter of fiscal 2025 at approximately 6:30am ET on Tuesday, August 5, 2025, followed by a conference call at 8:30am ET.

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and.

ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--FDA approves expanded indications for GE HealthCare's Vizamyl PET imaging agent for beta amyloid detection, enabling more precise care for Alzheimer's.

GEHC's Flyrcado gains momentum with FDA approval, CMS support, and expanding coverage in cardiac PET imaging.

CHICAGO--(BUSINESS WIRE)--Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development and research of innovative total body PET/CT technology.i This effort is expected to explore new clinical pathways and help enhance patient outcomes through innovative imaging solutions. “PET/CT has revolutionized the way we understand and treat disease by allowing us to visu.

Clermont-Ferrand (France), 27 May 2025 (17.45 CEST). CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces the signature of its first multi-year offtake contracts with L'ORÉAL and L'Occitane en Provence for biorecycled r-PET from its future commercial plant in Longlaville.

VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has entered into share exchange agreements to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”) (the “Transaction”). The Transaction moves Algernon into the Alzheimer's Disease (“AD”) diagnostic and treatment market, expanding on the Company's neurological research programs, and provides Algernon exclusive master franchise and licensing rights to open AD screening, diagnostic, and treatment centers across Canada and in multiple U.S. markets.